Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial

Journal of the Peripheral Nervous System : JPNS
C WalgaardDutch GBS study group

Abstract

One course of intravenous immunoglobulins (IVIg) of 2 g/kg is standard treatment in Guillain-Barré syndrome (GBS) patients unable to walk independently. Despite treatment some patients recover poorly, in part related to rapid consumption of IVIg, indicating that they may benefit from a second course of IVIg. The aim of the study is to determine whether a second course of IVIg, administered 1 week after start of the first course in patients with GBS and predicted poor outcome improves functional outcome on the GBS disability scale after 4 weeks. Secondary outcome measures include adverse events (AEs), Medical Research Council sumscore and GBS disability score after 8, 12, and 26 weeks, length of hospital and ICU admission, mortality, and changes in serum IgG levels. GBS patients of 12 years and older with a poor prognosis, based on the modified Erasmus GBS outcome score (mEGOS) at 1 week after start of the first IVIg course are eligible for randomization in this double-blind, placebo-controlled (IVIg or albumin) clinical trial. This study will determine if a second course of IVIg administered in the acute phase of the disease is safe, feasible, and effective in patients with GBS and a poor prognosis. This Dutch trial is register...Continue Reading

References

Oct 7, 1978·Lancet·R A HughesJ M Pierce
Jan 1, 1990·Annals of Neurology·A K Asbury, D R Cornblath
Aug 1, 1985·Neurology·P J Dyck, J F Kurtzke
Jan 1, 1997·Journal of Clinical Epidemiology·S C ScottN E Mayo
Feb 19, 2000·Neurology·R Van KoningsveldF G Van der Meché
Nov 8, 2005·Lancet·Richard A C Hughes, David R Cornblath
Mar 6, 2007·Brain : a Journal of Neurology·Richard A C HughesPieter A van Doorn
Nov 26, 2009·Annals of Neurology·Krista KuitwaardBart C Jacobs
Mar 16, 2011·Neurology·C WalgaardB C Jacobs
Mar 23, 2011·Neuroepidemiology·James J SejvarOliver W Morgan
Oct 22, 2013·Lancet Neurology·Andrew I R MaasUNKNOWN International Mission on Prognosis Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) Study Group
Jul 16, 2014·Nature Reviews. Neurology·Bianca van den BergPieter A van Doorn
Dec 19, 2014·Neurology. Neuroimmunology and Neuroinflammation·Thy P NguyenKazim Sheikh
Oct 16, 2015·Arquivos de neuro-psiquiatria·Daniel Agustin Godoy, Alejandro Rabinstein
Mar 8, 2016·Lancet·Hugh J WillisonPieter A van Doorn
Aug 5, 2016·Annals of Neurology·Patrick M Meyer SauteurBart C Jacobs
Aug 24, 2017·Journal of the Peripheral Nervous System : JPNS·Yuko YamagishiSusumu Kusunoki

❮ Previous
Next ❯

Citations

Sep 22, 2019·Nature Reviews. Neurology·Sonja E LeonhardBart C Jacobs
Oct 7, 2019·Journal of Neurology, Neurosurgery, and Psychiatry·Christine VerboonUNKNOWN IGOS Consortium
Jun 9, 2019·Neurology·Christine VerboonUNKNOWN IGOS Consortium
Apr 3, 2020·Rinshō shinkeigaku = Clinical neurology·Yuko Yamagishi, Susumu Kusunoki
Jun 12, 2020·Journal of Investigative Medicine High Impact Case Reports·Aditi Vian Varma-DoyleRadha Mayuri Garikepati
Jul 31, 2019·Nature Reviews. Neurology·Kalliopi Pitarokoili, Ralf Gold
Jan 19, 2019·Annals of Clinical and Translational Neurology·Maarten D BremRuth Huizinga
Nov 25, 2019·Internal Medicine Journal·Stephanie L Barnes, Geoffrey K Herkes
Jan 17, 2020·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·R KorinthenbergW Müller-Felber
Mar 2, 2021·Lancet·Nortina ShahrizailaSatoshi Kuwabara
May 18, 2021·Frontiers in Pharmacology·Pei ShangHong-Liang Zhang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of the Peripheral Nervous System : JPNS
Yuko YamagishiSusumu Kusunoki
Journal of Clinical Immunology
Pieter A van DoornBart C Jacobs
Rinshō shinkeigaku = Clinical neurology
Kenichi Kaida
Journal of the Peripheral Nervous System : JPNS
Amy I DavidsonHugh Willison
© 2022 Meta ULC. All rights reserved